Phobias
Conditions
Brief summary
The research team hopes to use brain imaging and mental testing to learn more about specific phobias and the treatment of phobia. When given directly prior to therapy sessions, D-cycloserine has been shown to enhance the effects of therapy. This study hopes to identify reasons why D-cycloserine has this effect by measuring brain activity.
Detailed description
Exposure and Response Prevention (ERP) therapy has become the treatment of choice for specific phobias. ERP involves systematic and repeated exposure to a feared or anxiety-provoking stimulus, leading to habituation and extinction of the fear response. Animal models of fear extinction have shown that acute administration of D-cycloserine (DCS) prior to exposure to a feared stimulus enhances extinction of that fear. A recent study in human subjects with height phobia (a specific phobia) has also demonstrated that DCS facilitates the effects of ERP therapy. Current theories postulate that DCS facilitates fear extinction by enhancing the learning process and increasing consolidation of memories, but the neural mechanisms underlying this process are not understood. The proposed research aims to elucidate these mechanisms by using fMRI to measure brain activation during 1) symptom provocation and verbal learning two hours post-medication, and 2)repeated symptom provocation and verbal recognition one week post-medication. This research will also examine the effects of DCS on cognitive functioning using neuropsychological testing both two house and one week post-medication.
Interventions
D-cycloserine
Placebo
Sponsors
Study design
Eligibility
Inclusion criteria
* Right-handed * Adults between 18 and 55 years of age * Subjects in the phobic group will additionally meet diagnostic (DSM-IV) criteria for spider phobia. * Individuals of both genders and all races will be included
Exclusion criteria
* Women who are breastfeeding or pregnant * Individuals with medical conditions unsuitable for MR scanning * Individuals reporting a history of epilepsy or seizures * Individuals reporting an allergy to cycloserine * Individuals diagnosed with asthma or who report previous anaphylactic reaction to insect stings/bites, medication, food, or other material and/or event * Individuals reporting present or past diagnosis of a developmental disorder, neurological disorder, or head injury \*Individuals found to have Axis I psychopathology as defined by the DSM-IV (other than spider phobia) * Individuals currently taking any psychotropic medication
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| fMRI Brain Activations During Symptom Provocation | 2 Weeks | Regions of interest (ROIs) were specified based on previous research and included amygdala, insula, dorsal anterior cingulate cortex (ACC), dorsolateral PFC (dlPFC), and hippocampus. Multiple regression analyses were used to examine differences in response between experimental conditions (spider versus butterfly images). For significant clusters of activation within ROIs, the average max percent signal change is reported. For other regions, the average max percent signal change is reported within a sphere centered at coordinates identified via previous research. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests) | 2 Weeks | This scale measures the learning and memory of functioning adults. Logical Memory I and II and Faces I and II subtests were administered to participants. The tasks measure verbal and visual memory, respectively. Scoring is based on the number of story details or faces correctly recalled during immediate (Logical Memory I, Faces I) and 30 minute delayed (Logical Memory II, Faces II) conditions. Total score ranges from 0-75 on Logical Memory I, 0-50 on Logical Memory II, 0-48 on Faces I, and 0-48 on Faces II. For all subtests, higher scores indicate better memory performance. |
| Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT) | 2 weeks | The RCFT assesses the a person's ability to use cues to retrieve information. The test measures visuospatial construction and memory. A person is asked to draw a figure. The figure is broken down into 18 elements. The score is based on their presence, completeness, and correct placement. Each element is scored from 0-2. The Copy, Immediate, and Delay results are scored on a 36 point scale. The higher the score, the better the person performed on the test with a 0 being the minimum and 36 being the maximum score. The organization score is scored according to whether the participant drew five cohesive units of the figure together, for a range of 0-6 and a higher score indicating better organizational performance. |
| Cognitive Functioning Measured Using the Iowa Gambling Test | 2 weeks | This test measures a person's emotional decision making. Participants are presented with virtual decks of cards on a computer. Participants are told that each card they draw will win them game money. However, sometimes cards result in losing game money. The task includes 100 trials and the total score represents the number of cards drawn from bad decks as compared to good or safe decks. Thus, the score ranges from -100 to +100, with higher sores representing better performance. |
| Cognitive Functioning Measured Using the Wisconsin Card Sorting Task | 2 weeks | The Wisconsin Card Sorting Task measures executive functioning and cognitive flexibility. The task uses a deck of 64 cards that the participant must sort according to specified rules. The test is stopped when when six sequences of 10 correct responses have been achieved, or after the deck has been completed twice, which provides a cumulative total of 128 trials. We report the number of errors on the task, which has a range of 0 -128, with a higher score representing worse performance. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Non-Phobic Control - Placebo Participants without phobia given one administration of placebo. | 14 |
| Non-Phobic Control - DCS Participants without phobia given one administration of 100 mg D-cycloserine (DCS). | 13 |
| Spider-phobic Placebo Participants with phobia given one administration of placebo. | 13 |
| Spider-phobic DCS Participants with phobia given one administration of 100 mg D-cycloserine (DCS). | 14 |
| Total | 54 |
Baseline characteristics
| Characteristic | Non-Phobic Control - Placebo | Non-Phobic Control - DCS | Spider-phobic Placebo | Spider-phobic DCS | Total |
|---|---|---|---|---|---|
| Age, Continuous | 23.09 years STANDARD_DEVIATION 3.7 | 26.75 years STANDARD_DEVIATION 9.09 | 26.00 years STANDARD_DEVIATION 8.06 | 24.73 years STANDARD_DEVIATION 6.65 | 25.65 years STANDARD_DEVIATION 7.78 |
| Sex: Female, Male Female | 10 Participants | 9 Participants | 7 Participants | 13 Participants | 39 Participants |
| Sex: Female, Male Male | 4 Participants | 4 Participants | 6 Participants | 1 Participants | 15 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 14 | 0 / 13 | 0 / 13 | 0 / 13 |
| other Total, other adverse events | 0 / 14 | 0 / 13 | 0 / 13 | 0 / 14 |
| serious Total, serious adverse events | 0 / 14 | 0 / 13 | 0 / 13 | 0 / 14 |
Outcome results
fMRI Brain Activations During Symptom Provocation
Regions of interest (ROIs) were specified based on previous research and included amygdala, insula, dorsal anterior cingulate cortex (ACC), dorsolateral PFC (dlPFC), and hippocampus. Multiple regression analyses were used to examine differences in response between experimental conditions (spider versus butterfly images). For significant clusters of activation within ROIs, the average max percent signal change is reported. For other regions, the average max percent signal change is reported within a sphere centered at coordinates identified via previous research.
Time frame: 2 Weeks
Population: There were 54 enrolled in the study. 8 subjects were excluded from fMRI analyses: 1 for claustrophobia, 3 for scanner artifact, 1 because of motion \>3mm; 3 of paradigm-consistent motion which could not be corrected for.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DCS Phobic | fMRI Brain Activations During Symptom Provocation | mid dorsal ACC Butterfly | .022 percent signal change | Standard Deviation 0.114 |
| DCS Phobic | fMRI Brain Activations During Symptom Provocation | Left hippocampus Butterfly | .010 percent signal change | Standard Deviation 0.18 |
| DCS Phobic | fMRI Brain Activations During Symptom Provocation | Right dlPFC Butterfly | .150 percent signal change | Standard Deviation 0.203 |
| DCS Phobic | fMRI Brain Activations During Symptom Provocation | Right dlPFC Spider | .384 percent signal change | Standard Deviation 0.286 |
| DCS Phobic | fMRI Brain Activations During Symptom Provocation | Left dlPFC Spider | .250 percent signal change | Standard Deviation 0.183 |
| DCS Phobic | fMRI Brain Activations During Symptom Provocation | Left hippocampus Spider | .101 percent signal change | Standard Deviation 0.222 |
| DCS Phobic | fMRI Brain Activations During Symptom Provocation | Left Insula Spider | .200 percent signal change | Standard Deviation 0.182 |
| DCS Phobic | fMRI Brain Activations During Symptom Provocation | Left dlPFC Butterfly | .031 percent signal change | Standard Deviation 0.122 |
| DCS Phobic | fMRI Brain Activations During Symptom Provocation | Right Insula Spider | .107 percent signal change | Standard Deviation 0.19 |
| DCS Phobic | fMRI Brain Activations During Symptom Provocation | Right hippocampus Spider | .113 percent signal change | Standard Deviation 0.315 |
| DCS Phobic | fMRI Brain Activations During Symptom Provocation | Left amygdala Butterfly | .127 percent signal change | Standard Deviation 0.139 |
| DCS Phobic | fMRI Brain Activations During Symptom Provocation | Right Insula Butterfly | .017 percent signal change | Standard Deviation 0.144 |
| DCS Phobic | fMRI Brain Activations During Symptom Provocation | Left Insula Butterfly | .012 percent signal change | Standard Deviation 0.139 |
| DCS Phobic | fMRI Brain Activations During Symptom Provocation | mid dorsal ACC Spider | .242 percent signal change | Standard Deviation 0.135 |
| DCS Phobic | fMRI Brain Activations During Symptom Provocation | Right amygdala Butterfly | .082 percent signal change | Standard Deviation 0.157 |
| DCS Phobic | fMRI Brain Activations During Symptom Provocation | Right hippocampus Butterfly | .017 percent signal change | Standard Deviation 0.103 |
| DCS Phobic | fMRI Brain Activations During Symptom Provocation | Right amygdala Spider | .241 percent signal change | Standard Deviation 0.157 |
| DCS Phobic | fMRI Brain Activations During Symptom Provocation | Left amygdala Spider | .322 percent signal change | Standard Deviation 0.182 |
| DCS Control | fMRI Brain Activations During Symptom Provocation | Left dlPFC Butterfly | .076 percent signal change | Standard Deviation 0.372 |
| DCS Control | fMRI Brain Activations During Symptom Provocation | Left Insula Spider | .157 percent signal change | Standard Deviation 0.373 |
| DCS Control | fMRI Brain Activations During Symptom Provocation | Left Insula Butterfly | .021 percent signal change | Standard Deviation 0.376 |
| DCS Control | fMRI Brain Activations During Symptom Provocation | Right Insula Spider | .174 percent signal change | Standard Deviation 0.287 |
| DCS Control | fMRI Brain Activations During Symptom Provocation | Right Insula Butterfly | .109 percent signal change | Standard Deviation 0.221 |
| DCS Control | fMRI Brain Activations During Symptom Provocation | mid dorsal ACC Spider | .402 percent signal change | Standard Deviation 0.459 |
| DCS Control | fMRI Brain Activations During Symptom Provocation | mid dorsal ACC Butterfly | .053 percent signal change | Standard Deviation 0.166 |
| DCS Control | fMRI Brain Activations During Symptom Provocation | Left dlPFC Spider | .122 percent signal change | Standard Deviation 0.361 |
| DCS Control | fMRI Brain Activations During Symptom Provocation | Right dlPFC Spider | .521 percent signal change | Standard Deviation 0.676 |
| DCS Control | fMRI Brain Activations During Symptom Provocation | Right dlPFC Butterfly | .431 percent signal change | Standard Deviation 0.585 |
| DCS Control | fMRI Brain Activations During Symptom Provocation | Left amygdala Spider | .202 percent signal change | Standard Deviation 0.308 |
| DCS Control | fMRI Brain Activations During Symptom Provocation | Left amygdala Butterfly | .149 percent signal change | Standard Deviation 0.137 |
| DCS Control | fMRI Brain Activations During Symptom Provocation | Right amygdala Spider | .155 percent signal change | Standard Deviation 0.347 |
| DCS Control | fMRI Brain Activations During Symptom Provocation | Right amygdala Butterfly | .181 percent signal change | Standard Deviation 0.244 |
| DCS Control | fMRI Brain Activations During Symptom Provocation | Left hippocampus Spider | .196 percent signal change | Standard Deviation 0.217 |
| DCS Control | fMRI Brain Activations During Symptom Provocation | Left hippocampus Butterfly | .065 percent signal change | Standard Deviation 0.112 |
| DCS Control | fMRI Brain Activations During Symptom Provocation | Right hippocampus Spider | .310 percent signal change | Standard Deviation 0.224 |
| DCS Control | fMRI Brain Activations During Symptom Provocation | Right hippocampus Butterfly | .219 percent signal change | Standard Deviation 0.203 |
| Placebo Phobic | fMRI Brain Activations During Symptom Provocation | Right hippocampus Spider | .075 percent signal change | Standard Deviation 0.193 |
| Placebo Phobic | fMRI Brain Activations During Symptom Provocation | Left Insula Spider | -.013 percent signal change | Standard Deviation 0.167 |
| Placebo Phobic | fMRI Brain Activations During Symptom Provocation | Right amygdala Spider | .183 percent signal change | Standard Deviation 0.336 |
| Placebo Phobic | fMRI Brain Activations During Symptom Provocation | Right hippocampus Butterfly | .155 percent signal change | Standard Deviation 0.118 |
| Placebo Phobic | fMRI Brain Activations During Symptom Provocation | Left hippocampus Spider | .185 percent signal change | Standard Deviation 0.184 |
| Placebo Phobic | fMRI Brain Activations During Symptom Provocation | Left amygdala Butterfly | .254 percent signal change | Standard Deviation 0.157 |
| Placebo Phobic | fMRI Brain Activations During Symptom Provocation | Left Insula Butterfly | .092 percent signal change | Standard Deviation 0.162 |
| Placebo Phobic | fMRI Brain Activations During Symptom Provocation | Left amygdala Spider | .534 percent signal change | Standard Deviation 0.272 |
| Placebo Phobic | fMRI Brain Activations During Symptom Provocation | Right amygdala Butterfly | .203 percent signal change | Standard Deviation 0.216 |
| Placebo Phobic | fMRI Brain Activations During Symptom Provocation | Left dlPFC Spider | .019 percent signal change | Standard Deviation 0.118 |
| Placebo Phobic | fMRI Brain Activations During Symptom Provocation | Left dlPFC Butterfly | .035 percent signal change | Standard Deviation 0.154 |
| Placebo Phobic | fMRI Brain Activations During Symptom Provocation | Right Insula Spider | -.004 percent signal change | Standard Deviation 0.087 |
| Placebo Phobic | fMRI Brain Activations During Symptom Provocation | Right Insula Butterfly | .133 percent signal change | Standard Deviation 0.139 |
| Placebo Phobic | fMRI Brain Activations During Symptom Provocation | Left hippocampus Butterfly | .204 percent signal change | Standard Deviation 0.17 |
| Placebo Phobic | fMRI Brain Activations During Symptom Provocation | Right dlPFC Spider | .301 percent signal change | Standard Deviation 0.349 |
| Placebo Phobic | fMRI Brain Activations During Symptom Provocation | mid dorsal ACC Butterfly | .085 percent signal change | Standard Deviation 0.123 |
| Placebo Phobic | fMRI Brain Activations During Symptom Provocation | mid dorsal ACC Spider | .073 percent signal change | Standard Deviation 0.171 |
| Placebo Phobic | fMRI Brain Activations During Symptom Provocation | Right dlPFC Butterfly | .249 percent signal change | Standard Deviation 0.42 |
| Placebo Control | fMRI Brain Activations During Symptom Provocation | Right Insula Spider | .020 percent signal change | Standard Deviation 0.25 |
| Placebo Control | fMRI Brain Activations During Symptom Provocation | mid dorsal ACC Spider | .071 percent signal change | Standard Deviation 0.18 |
| Placebo Control | fMRI Brain Activations During Symptom Provocation | Left Insula Spider | .036 percent signal change | Standard Deviation 0.095 |
| Placebo Control | fMRI Brain Activations During Symptom Provocation | Left amygdala Spider | .427 percent signal change | Standard Deviation 0.244 |
| Placebo Control | fMRI Brain Activations During Symptom Provocation | Left amygdala Butterfly | .098 percent signal change | Standard Deviation 0.299 |
| Placebo Control | fMRI Brain Activations During Symptom Provocation | Right amygdala Spider | .133 percent signal change | Standard Deviation 0.23 |
| Placebo Control | fMRI Brain Activations During Symptom Provocation | Right Insula Butterfly | .017 percent signal change | Standard Deviation 0.211 |
| Placebo Control | fMRI Brain Activations During Symptom Provocation | Right hippocampus Spider | .361 percent signal change | Standard Deviation 0.347 |
| Placebo Control | fMRI Brain Activations During Symptom Provocation | Right dlPFC Spider | .038 percent signal change | Standard Deviation 0.464 |
| Placebo Control | fMRI Brain Activations During Symptom Provocation | Right dlPFC Butterfly | .110 percent signal change | Standard Deviation 0.31 |
| Placebo Control | fMRI Brain Activations During Symptom Provocation | Right amygdala Butterfly | -.017 percent signal change | Standard Deviation 0.273 |
| Placebo Control | fMRI Brain Activations During Symptom Provocation | Left Insula Butterfly | .079 percent signal change | Standard Deviation 0.147 |
| Placebo Control | fMRI Brain Activations During Symptom Provocation | Left hippocampus Spider | .131 percent signal change | Standard Deviation 0.206 |
| Placebo Control | fMRI Brain Activations During Symptom Provocation | Right hippocampus Butterfly | .329 percent signal change | Standard Deviation 0.283 |
| Placebo Control | fMRI Brain Activations During Symptom Provocation | Left dlPFC Spider | .278 percent signal change | Standard Deviation 0.3 |
| Placebo Control | fMRI Brain Activations During Symptom Provocation | Left dlPFC Butterfly | .075 percent signal change | Standard Deviation 0.435 |
| Placebo Control | fMRI Brain Activations During Symptom Provocation | mid dorsal ACC Butterfly | -.059 percent signal change | Standard Deviation 0.244 |
| Placebo Control | fMRI Brain Activations During Symptom Provocation | Left hippocampus Butterfly | .086 percent signal change | Standard Deviation 0.158 |
Cognitive Functioning Measured Using the Iowa Gambling Test
This test measures a person's emotional decision making. Participants are presented with virtual decks of cards on a computer. Participants are told that each card they draw will win them game money. However, sometimes cards result in losing game money. The task includes 100 trials and the total score represents the number of cards drawn from bad decks as compared to good or safe decks. Thus, the score ranges from -100 to +100, with higher sores representing better performance.
Time frame: 2 weeks
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| DCS Phobic | Cognitive Functioning Measured Using the Iowa Gambling Test | 44.29 units on a scale | Standard Deviation 23.68 |
| DCS Control | Cognitive Functioning Measured Using the Iowa Gambling Test | 32.62 units on a scale | Standard Deviation 26.76 |
| Placebo Phobic | Cognitive Functioning Measured Using the Iowa Gambling Test | 28.58 units on a scale | Standard Deviation 21.89 |
| Placebo Control | Cognitive Functioning Measured Using the Iowa Gambling Test | 21.85 units on a scale | Standard Deviation 28.42 |
Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT)
The RCFT assesses the a person's ability to use cues to retrieve information. The test measures visuospatial construction and memory. A person is asked to draw a figure. The figure is broken down into 18 elements. The score is based on their presence, completeness, and correct placement. Each element is scored from 0-2. The Copy, Immediate, and Delay results are scored on a 36 point scale. The higher the score, the better the person performed on the test with a 0 being the minimum and 36 being the maximum score. The organization score is scored according to whether the participant drew five cohesive units of the figure together, for a range of 0-6 and a higher score indicating better organizational performance.
Time frame: 2 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DCS Phobic | Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT) | Organization | 4.93 units on a scale | Standard Deviation 1.33 |
| DCS Phobic | Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT) | Copy | 34.68 units on a scale | Standard Deviation 2.49 |
| DCS Phobic | Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT) | Delay | 26.08 units on a scale | Standard Deviation 3.81 |
| DCS Phobic | Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT) | Immediate | 26.54 units on a scale | Standard Deviation 3.97 |
| DCS Control | Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT) | Copy | 34.46 units on a scale | Standard Deviation 3.53 |
| DCS Control | Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT) | Immediate | 24.77 units on a scale | Standard Deviation 6.66 |
| DCS Control | Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT) | Delay | 23.35 units on a scale | Standard Deviation 7.11 |
| DCS Control | Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT) | Organization | 4.92 units on a scale | Standard Deviation 1.55 |
| Placebo Phobic | Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT) | Copy | 34.46 units on a scale | Standard Deviation 2.15 |
| Placebo Phobic | Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT) | Immediate | 26.17 units on a scale | Standard Deviation 3.76 |
| Placebo Phobic | Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT) | Organization | 3.69 units on a scale | Standard Deviation 1.97 |
| Placebo Phobic | Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT) | Delay | 26.13 units on a scale | Standard Deviation 2.57 |
| Placebo Control | Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT) | Immediate | 26.14 units on a scale | Standard Deviation 5.46 |
| Placebo Control | Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT) | Organization | 4.14 units on a scale | Standard Deviation 1.96 |
| Placebo Control | Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT) | Delay | 25.64 units on a scale | Standard Deviation 5.36 |
| Placebo Control | Cognitive Functioning Measured Using the Rey-Osterrieth Complex Figure Test (RCFT) | Copy | 34.50 units on a scale | Standard Deviation 1.95 |
Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests)
This scale measures the learning and memory of functioning adults. Logical Memory I and II and Faces I and II subtests were administered to participants. The tasks measure verbal and visual memory, respectively. Scoring is based on the number of story details or faces correctly recalled during immediate (Logical Memory I, Faces I) and 30 minute delayed (Logical Memory II, Faces II) conditions. Total score ranges from 0-75 on Logical Memory I, 0-50 on Logical Memory II, 0-48 on Faces I, and 0-48 on Faces II. For all subtests, higher scores indicate better memory performance.
Time frame: 2 Weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| DCS Phobic | Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests) | Faces 2 | 41.93 units on a scale | Standard Deviation 2.09 |
| DCS Phobic | Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests) | Logical Memory 1 | 51.93 units on a scale | Standard Deviation 8.91 |
| DCS Phobic | Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests) | Logical Memory 2 | 34.36 units on a scale | Standard Deviation 6.67 |
| DCS Phobic | Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests) | Faces 1 | 40.43 units on a scale | Standard Deviation 3.2 |
| DCS Control | Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests) | Logical Memory 2 | 32.46 units on a scale | Standard Deviation 7.03 |
| DCS Control | Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests) | Logical Memory 1 | 49 units on a scale | Standard Deviation 9.24 |
| DCS Control | Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests) | Faces 2 | 41.62 units on a scale | Standard Deviation 2.99 |
| DCS Control | Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests) | Faces 1 | 41.85 units on a scale | Standard Deviation 2.73 |
| Placebo Phobic | Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests) | Logical Memory 2 | 34.85 units on a scale | Standard Deviation 8.21 |
| Placebo Phobic | Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests) | Logical Memory 1 | 52.69 units on a scale | Standard Deviation 10.3 |
| Placebo Phobic | Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests) | Faces 1 | 41 units on a scale | Standard Deviation 4.28 |
| Placebo Phobic | Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests) | Faces 2 | 41.62 units on a scale | Standard Deviation 3.43 |
| Placebo Control | Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests) | Faces 1 | 42.07 units on a scale | Standard Deviation 3.83 |
| Placebo Control | Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests) | Logical Memory 1 | 52.93 units on a scale | Standard Deviation 7.56 |
| Placebo Control | Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests) | Logical Memory 2 | 35.43 units on a scale | Standard Deviation 5.2 |
| Placebo Control | Cognitive Functioning Measured Using the Wechsler Memory Scale III (Logical Memory and Faces Subtests) | Faces 2 | 42.07 units on a scale | Standard Deviation 3.97 |
Cognitive Functioning Measured Using the Wisconsin Card Sorting Task
The Wisconsin Card Sorting Task measures executive functioning and cognitive flexibility. The task uses a deck of 64 cards that the participant must sort according to specified rules. The test is stopped when when six sequences of 10 correct responses have been achieved, or after the deck has been completed twice, which provides a cumulative total of 128 trials. We report the number of errors on the task, which has a range of 0 -128, with a higher score representing worse performance.
Time frame: 2 weeks
Population: Two subjects did not complete the test because they had previous exposure to the test.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| DCS Phobic | Cognitive Functioning Measured Using the Wisconsin Card Sorting Task | 13.29 units on a scale | Standard Deviation 6.98 |
| DCS Control | Cognitive Functioning Measured Using the Wisconsin Card Sorting Task | 13.62 units on a scale | Standard Deviation 7.65 |
| Placebo Phobic | Cognitive Functioning Measured Using the Wisconsin Card Sorting Task | 18.23 units on a scale | Standard Deviation 16.58 |
| Placebo Control | Cognitive Functioning Measured Using the Wisconsin Card Sorting Task | 15.67 units on a scale | Standard Deviation 9.33 |